中国日报网8d
Novartis China Patient Day event held in Shanghai
Leo Lee, president and managing director of Novartis China delivers a speech at the second Novartis China Patient Day event held in Shanghai on Friday. [Photo provided to chinadaily.com.cn] Themed ...
emjreviews.com10d
Boehringer, Amgen and Novartis rank top for cardiovascular patient groups
Find out why Boehringer, Amgen and Novartis have been awarded the highest reputation scores by several cardiovascular patient ...
emjreviews.com11d
Is Remission Now an Achievable Goal for More Patients with Systemic Lupus Erythematosus?
SLE is a chronic and complex heterogeneous autoimmune disease in which the immune system dysfunctions and inappropriately ...
Pharmaceutical Technology11d
Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions
Experts predict that physicians may favour emerging biosimilar versions of Stelara over more effective originator IL-23 drugs ...
Pharmabiz11d
US FDA grants accelerated approval to Novartis’ Scemblix for adult patients with newly diagnosed Ph+ CML-CP
US FDA grants accelerated approval to Novartis’ Scemblix for adult patients with newly diagnosed Ph+ CML-CP: East Hanover Thursday, October 31, 2024, 12:00 Hrs [IST] Novartis an ...
ThePrint on MSN12d
In Delhi hospitals, thalassemia patients suffer as life-saving Desferal scarce, set to become 50% costlier
Doctors & patients confirm acute shortage of the drug in hospitals, even as manufacturer Novartis maintains there is no ...
Novartis12d
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...
Novartis Pharma AG: Novartis Scemblix FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial ...
BioSpace14d
Novartis Inks Potential $2.2B Molecular Glue Deal With Monte Rosa
Novartis on Monday became the latest Big Pharma player to jump into the molecular glue space. The Swiss drugmaker signed an exclusive development and commercialization agreement with Monte Rosa ...
Novartis24d
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
“If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population ... International, Novartis. “Together with ...
news.bloomberglaw24d
Novartis Sued for Gender, Age Discrimination by Female Managers
Novartis Pharmaceuticals Corp. was sued Thursday in federal court by four female pharmaceutical sales managers who say the company discriminated against them based on their age and gender when they ...
FiercePharma25d
Novartis falls short in legal effort to undo FDA approval of MSN's Entresto generic
As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss pharma’s top-selling drug Entresto. In a court decision filed this ...